MM-014: A phase 2 trial evaluating efficacy, safety, and biomarkers of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) following second-line lenalidomide plus dexamethasone (LEN + DEX).
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Merck; Millennium; Onyx
Honoraria - Celgene; Merck; Millennium; Onyx
Richy Agajanian
No relevant relationships to disclose
Rakesh Gaur
No relevant relationships to disclose
Kasra Karamlou
Consultant or Advisory Role - Genentech
Honoraria - Bristol-Myers Squibb; Celgene; Genentech; Incyte; Millennium; Pharmacyclics; Teva
Hakan Kaya
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium; Onyx
Michael Sturniolo
Employment or Leadership Position - Celgene
Rosanna J. Ricafort
Employment or Leadership Position - Celgene
Gail Larkins
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Shankar Srinivasan
Employment or Leadership Position - Celgene
Rajesh Chopra
Employment or Leadership Position - Celgene
Anjan Thakurta
Employment or Leadership Position - Celgene
Yasir M. Nagarwala
Employment or Leadership Position - Celgene
Flavio Kruter
No relevant relationships to disclose